Hepatotropic viruses: New insights in pathogenesis and treatment

Clinical and Experimental Rheumatology

Volumn 26, Issue 1 SUPPL. 48, 2008, Pages

  Gatta, Angelo ^a   Giannini, Carlo ^b   Lampertico, Pietro ^c   Pontisso, Patrizia ^a   Quarta, Santina ^a   Zignego, Anna Linda ^b   Atzeni, Fabiola ^d   Sarzi Puttini, Piercarlo ^d  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

Author keywords

Combination treatment; HBV virus; Infected peripheral blood mononuclear cells; Lamivudine; Peginterferon

Indexed keywords

ADEFOVIR; ENTECAVIR; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; NUCLEOSIDE DERIVATIVE; PEGINTERFERON; PEGINTERFERON ALPHA2A; TELBIVUDINE;

ADD ON THERAPY; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CLINICAL TRIAL; CRYOGLOBULINEMIA; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS VIRUS; HUMAN; LYMPHOCYTE PROLIFERATION; LYMPHOMA; MONOCYTE; MONOTHERAPY; NONHODGKIN LYMPHOMA; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REVIEW; VERTICAL TRANSMISSION; VIRUS REPLICATION; VIRUS TRANSMISSION;

ANTIVIRAL AGENTS; HEPACIVIRUS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS;

EID: 42549092711     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. PONTISSO P, POON MC, TIOLLAIS P, BRECHOT C: Detection of hepatitis B virus DNA in mononuclear blood cells. Br Med J 1984; 288: 1563-66.
2. ROMET-LEMONNE JP, EL-FASSI E, HASELTINE W et al.: Infection of bone marrow cells by hepatitis B virus. Lancet 1983; 2:732.
3. ROMET-LEMONNE JP, MCLANE MF, ELFASSI E et al.: Hepatitis B virus infection in cultured human lymphoblastoid cells. Science 1983; 221: 667-69.
4. CATTERALL AP, MURRAY-LYON IM, ZUCKERMAN AJ, HARRISON TJ: Southern hybridization analysis of HBV DNA in peripheral blood leucocytes and of different cell types: Changes during the natural history and with interferon-alpha therapy in patients with hepatitis B virus infection. J Med Virol 1994; 43: 269-75.
5. MICHALAK TL, PASQUINELLI C, GUILHOT S, CHISARI FV: Hepatitis B virus persistence after recovery from acute viral hepatitis. J Clin Invest 1994, 93: 230-9.
6. KORBA BE, COTE PJ, SHAPIRO M, PURCELL RH, GERIN JL: In vitro production of infectious woodchuck hepatitis virus by lipopolysaccharide-stimulated peripheral blood lymphocytes. J Infect. Dis 1989; 160: 572-6.
7. CABRERIZO M, BARTOLOMÈ J, DE SEQUERA P, CARAMELO P, CARRENO v: Hepatitis B virus DNA in serum and blood cells of hepatitis B surface antigen-negative hemodialysis in patients and staff. J Am Soc Nephrol 1997; 8: 1443-7.
8. HAN XB, YUE YE, BAI GQ, LI SH, SHI ZY: Clinical significance of detecting neonatal peripheral blood mononuclear cells infected by HBV. Zhonghua Er Ke Zhi 2005; 43: 434-47.
9. TRIPPLER M, MEYER ZUM BUSCHENFELDE KH, GERKEN G: HBV viral load within subpopulations of peripheral blood mononuclear cells in HBV infection using limiting dilution PCR. J Virol Methods 1999; 78: 129-47.
10. PONTISSO P, MORSICA G, RUVOLETTO MG et al.: Hepatitis B virus binds to peripheral blood mononuclear cells via the preS1 domain. J Hepatol 1991; 12: 203-6.
11. ZIGNEGO, AL, MACCHIA D, MONTI M et al.: Infection of peripheral mononuclear blood cells by hepatitis C virus. J Hepatol 1992; 15: 382-6.
12. ZIGNEGO AL, GIANNINI C, MONTI M, GRAGNANI L: Hepatitis C virus lymphotropism: Lessons from a decade of studies. Dig Liver Dis 2007; 39: S38-45.
13. ZIGNEGO AL, GIANNINI C, FERRI C: Hepatitis C virus-related lymphoproliferative disorders: An overview. World J Gastroenterol 2007; 13: 2467-8.
14. ZIGNEGO AL, FERRI C, PILERI SA, CAINI P, BIANCHI FB: Extrahepatic manifestations of Hepatitis C Virus infection: A general overview and guidelines for a clinical approach. Dig Liver Dis 2007; 39: 2-17.
15. FERRI C, PILERI S, ZIGNEGO AL: Hepatitis C virus infection and non-Hodgkin's lymphoma. In GEODERT J, (NIH) NCI, (Ed.) Infectious causes of cancer. Targets for intervention. Totowa, New Jersey: The Human Press Inc 2000; 349-68.
16. FERRI C, SEBASTIANI M, GIUGGIOLI D et al.: Mixed cryoglobulinemia: Demographic, clinical, and serologic features and survival in 231 patients. Semin Arthritis Rheum 2004; 33: 355-74.
17. FERRI C, ZIGNEGO AL, PILERI SA: Cryoglobulins. J Clin Pathol 2002; 55: 4-13.
18. PAGNOUX C, COHEN P, GUILLEVIN L: Vasculitides secondary to infections. Clin Exp Rheumatol 2006; 24: S71-81.
19. ROZIN AP, LEWIN M, BRAUN-MOSCOVICI Y, ITZHAK OB, BERGMAN R, BALBIR-GURMAN A: Essential mixed cryoglobulinemia type II. Clin Exp Rheumatol 2006; 24: 329-32.
20. FERRI C, ZIGNEGO AL, PILERI S: Cryoglobulins. In: Clinical Hematology. Chapter 24: Elsevier (Mosby), 2005; 625-36.
21. HERMINE O, LEFRERE F, BRONOWICKI JP et al.: Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med 2002; 347: 89-94.
22. ZIGNEGO AL, GIANNELLI F, MARROCCHI ME et al.: Frequency of bcl-2 rearrangement in patients with mixed cryoglobulinemia and HCV-positive liver diseases. Clin Exp Rheamatol 1997; 15: 711-2.
23. ZIGNEGO AL, GIANNELLI F, MARROCCHI ME et al.: T(14; 18) translocation in chronic hepatitis C virus infection. Hepatology 2000; 31: 474-9.
24. ZIGNEGO AL, FERRI C, GIANNELLI F et al.: Prevalence of bcl-2 rearrangement in patients with hepatitis C virus-related mixed cryoglobulinemia with or without B-cell lymphomas. Ann Intern Med 2002; 137: 571-80.
25. MONTEVERDE A,FINVERNIZZI F: Hepatitis C virus: from biology to clinical practice. Clin Exp Rheumatol 1995; 13: S205-10.
26. ALISI A, GIANNINI C, SPAZIANI A, CAINI P, ZIGNEGO AL, BALSANO C: Involvement of PI3K in HCV-related lymphoproliferative disorders. J Cell Physiol 2008; 214: 396-404.
27. ZIGNEGO AL, FONTANA R, PULITI S et al.: Relevance of inapparent coinfection by hepatitis B virus in alpha interferon-treated patients with hepatitis C virus chronic hepatitis. J Med Virol 1997; 51: 313-8.
28. CACCIOLA I, POLLICINO T, SQUADRITO G, CERENZIA G, ORLANDO ME, RAIMONDO G: Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med 1999; 341: 22-6.
29. SQUADRITO G, POLLICINO T, CACCIOLA I et al.: Occult hepatitis B virus infection is associated with the development of hepatocellular carcinoma in chronic hepatitis C patients. Cancer 2006; 106: 1326-30.
30. ULCICKAS YOOD M, QUESENBERRY CP et al.: Incidence of non-Hodgkin's lymphoma among individuals with chronic hepatitis B virus infection. Hepatology 2007; 46: 107-12.
31. MARCELLIN P, LAU GKK, BONINO F et al.: Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351: 1206-17.
32. MARCELLIN P, BONINO F, LAU GK et al.: Virological and biochemical response in patients with HBeAg-negative CHB treated with peginterferon alfa-2a (40kd) ± lamivudine: 3-year follow-up results. J Hepatol 2007; 46: S25.
33. HADZIYANNIS SJ, PAPATHEODORIDIS GV, DIMOU E et al.: Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2000; 32: 847-51.
34. DI MARCO V, MARZANO A, LAMPERTICO P et al.: Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. Hepatology 2004; 40: 883-91.
35. HADZIYANNIS SJ, TASSOPOULOS NC, HEATHCOTE EJ et al.: Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006; 131: 1743-51.
36. HADZIYANNIS S, SEVASTIANOS V, RAPTI IN et al.: Sustained biochemical and virological remission after discontinuation of 4 to 5 years of adefovir dipivoxil (ADV) treatment in HBeAg negative chronic hepatitis B. Hepatology 2006; 44; 231A.
37. LAI CL, SHOUVAL D, LOK AS et al.: Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006; 354: 1011-20.
38. SHOUVAL D, AKARCA US, HATZIS G et al.: Continued virologic and biochemical improvement through 96 weeks of entecavir treatment in HBeAg(-) chronic hepatitis B patients (Study ETV-027). J Hepatol 2006; 44: S21.
39. COLONNO RJ, ROSE RE, POKORNOWSKI K: Four-year assessment of ETV resistance in nucleoside-naïve and lamivudine refractory patients. J Hepatol 2007; 46: S294.
40. LAI CL, GANE E, HSU CW et al.: Two-year results from the Globe trial in patients with hepatitis B: Greater clinical and antiviral efficacy for Telbivudine (LdT) vs. Lamivudine. Hepatology 2006; 44; 222.
41. DI BISCEGLIE A. LAI CL, GANE E et al.: Tel-bivudine Globe trial: maximal early HBV suppression is predictive of optimal two-year efficacy in nucleoside-treated hepatitis B patients. Hepatology 2006; 44; 230.
42. PAPATHEODORIDIS GV, DIMOU E, DIMAKOPOULOS K et al.: Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine. Hepatology 2005; 42: 121-9.
43. LAMPERTICO P, VIGANÒ M, MANENTI E et al.: Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. Hepatology 2005; 42: 1414-9.
44. RAPTI I, DIMOU E, MITSOULA P et al.: Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology 2007; 45: 307-13.
45. LAMPERTICO P, MARZANO A, LEVRERO M et al.: Adefovir and lamivudine combination therapy is superior to adefovir monotherapy for lamivudine-resistant patients with HBeAg-negative chronic hepatitis B. J Hepatol 2007; 46: S191.
46. LAMPERTICO P, VIGANÒ M, MANENTI E et al.: Low resistance to adefovir combined with lamivudine: A 3-year study of 145 lamivudine resistant hepatitis B patients. Gastroenterology 2007; 133: 1445-51.
47. IAVARONE M, LAMPERTICO P, VIGANÒ M: Six years of on demand LAM ± ADV combination therapy significantly reduces the development and progression of esophageal varices in patients with HBeAg-negative cirrhosis. J Hepatol 2007; 46: S189.
48. SHERMAN M, YURDAYDIN C, SOLLANO J et al.: Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology 2006; 130: 2039-49.